Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

The value of YKL-40 in ischemic heart disease patients

The Egyptian Journal of Internal Medicine volume 28, pages 71–77 (2016)Cite this article

Abstract

Introduction

Atherosclerotic coronary artery disease is considered to be the most common cause of myocardial ischemia. YKL-40, a chitin-binding acute phase glycoprotein, has been found to be expressed by macrophages in atherosclerotic plaques. The YKL-40 could potentially be a new useful biomarker to monitor severity and predict early diagnosis of acute coronary syndrome (ACS) in ischemic heart disease (IHD) patients.

Aim

The aim of this study was to measure the level of serum YKL-40 in IHD patients and to clarify its role as a potentially beneficial diagnostic marker in those patients.

Patients and methods

Serum YKL-40 was measured in 60 IHD patients and 30 healthy controls. According to chest pain analysis, ECG changes, and cardiac enzymes, the IHD patients were categorized into patients with stable angina and patients with ACS.

Results

The median level of YKL-40 (pg/ml) was significantly elevated in patients with IHD compared with the control group (2080 (575.5–5974.6) vs 522.6 (133.2–769.5), respectively; P<0.001). The median level of YKL-40 was also significantly higher in patients with ACS compared with patients with stable angina (2436 (576–5975) vs 1015 (675–1822), respectively; P<0.001). There was a positive correlation between YKL-40 levels and high-sensitivity C-reactive protein (mg/dl) in all studied groups of IHD patients. However, no significant correlation was detected between YKL-40 and age, systolic or diastolic blood pressure, and lipid profile in patients with IHD.

Conclusion

YKL-40 might play an important role as a diagnostic and prognostic marker in patients with IHD and in patients with ACS.

References

  1. Azeredo-Da-Silva AL, Perini S, Rigotti Soares PH, Anne Polaczyk C. Systematic review of economic evaluations of units dedicated to acute coronary syndromes. Value Health 2016; 19: 286–295.

    Article  Google Scholar 

  2. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372: 1174–1183.

    Article  CAS  Google Scholar 

  3. Antman E, Selwyn A, Loscalzo J. Ischemic heart disease harrisons principles of internal medicine, 18e. New York, NY: McGraw-Hill; 2014; 1514–1527.

  4. Fiechter M, Ghadri JR, Jaguszewski M, Siddique A, Vogt S, Haller RB, et al. Impact of inflammation on adverse cardiovascular events in patients with acute coronary syndromes. J Cardiovasc Med (Hagerstown) 2013; 14: 807–814.

    Article  CAS  Google Scholar 

  5. Amit K, Christopher P. Acute coronary syndromes: diagnosis and management, Part I. Mayo Clin Proc 2009; 84: 917–938.

    Article  Google Scholar 

  6. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011; 73: 479–501.

    Article  CAS  Google Scholar 

  7. Johansen J. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer. Dan Med Bull 2006; 53: 172–209

    CAS  PubMed  Google Scholar 

  8. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992; 7: 501–512.

    Article  CAS  Google Scholar 

  9. Rehli M, Krause S, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 43: 221–225.

    Article  CAS  Google Scholar 

  10. Brøchner CB, Johansen JS, Larsen LA, Bak M, Mikkelsen HB, Byskov AG, et al. YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem 2012; 60: 188–204.

    Article  Google Scholar 

  11. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macro-phage differentiation. J Biol Chem 2003; 278: 44058–44067.

    Article  CAS  Google Scholar 

  12. Boussac M, Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 2000; 21: 665–672.

    Article  CAS  Google Scholar 

  13. Nishikawa K, Millis A. Gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003; 287: 79–87.

    Article  CAS  Google Scholar 

  14. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009; 30: 1066–1072.

    Article  CAS  Google Scholar 

  15. Mygind N, Kastrup J. YKL-40 as biomarker: focus on cardiovascular disease. In: Preedy VR, Patel VB, (Eds.), General methods in biomarker research and their applications, part V. New York London: Springer Dordrecht Heidelberg; 2015. 783–810.

  16. Abel N, Contino K, Jain N, Grewal N, Grand E, Hagans I, et al. Eighth Joint National Committee (JNC-8) Guidelines and the Outpatient Management of Hypertension in the African-American Population. N Am J Med Sci 2015; 7: 438–445.

    Article  Google Scholar 

  17. Rathcke C, Vestergaard H. YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009; 8: 1–7.

    Article  Google Scholar 

  18. Rathcke CN, Kistorp C, Raymond I, Hildebrandt P, Gustafsson F, Lip GY, et al. Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand Cardiovasc J 2010; 44: 92–99.

    Article  CAS  Google Scholar 

  19. Song CL, Li B, Diao HY, Wang JH, Shi Y, Lu Y, et al. Diagnostic value of serum YKL-40 level for coronary artery disease: a meta-analysis. J Clin Lab Anal 2014; 30: 1–9.

    Google Scholar 

  20. Nøjgaard C, Høst NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008; 19: 257–263.

    Article  Google Scholar 

  21. Hedegaard A, Ripa RS, Johansen JS, Jørgensen E, Kastrup J. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 2010; 70: 80–86.

    Article  CAS  Google Scholar 

  22. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 2008; 42: 295–302.

    Article  CAS  Google Scholar 

  23. Cetin M, Kocaman SA, Canga A, Kırbaş A, Yılmaz A, Erdoğan T, et al. Elevated serum YKL-40 level predicts myocardial reperfusion and in hospital MACE in patients with STEMI. Herz 2013; 38: 202–209.

    Article  CAS  Google Scholar 

  24. Mathiasen AB, Harutyunyan MJ, Jørgensen E, Helqvist S, Ripa R, Gøtze JP, et al. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand J Clin Lab Invest 2011; 71: 439–447.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Internal Medicine, Al-Azhar University, Cairo, Egypt

    Doaa S. E. Zaky MD & Fatma M. Mabrouk

  2. Cardiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt

    Eman R. Zaki

  3. Department of Clinical Pathology, National Liver Institute, Menofia University, Al Minufya, Egypt

    Olfat M. Hendy

Authors
  1. Doaa S. E. Zaky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatma M. Mabrouk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eman R. Zaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olfat M. Hendy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Doaa S. E. Zaky MD.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaky, D.S.E., Mabrouk, F.M., Zaki, E.R. et al. The value of YKL-40 in ischemic heart disease patients. Egypt J Intern Med 28, 71–77 (2016). https://doi.org/10.4103/1110-7782.193891

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1110-7782.193891

Keywords